Named on 3 rounds in the feed, most often in Biotech.
Rounds from 2026-01-08 to 2026-11-09
ROUNDS
3
led every one
LED ROUNDS · USD
$133.5M
across 3 rounds · 2 co-led, split evenly
CO-INVESTORS
22
most often with Samsara BioCapital
Named on 3 rounds in the feed, most often in Biotech.
Rounds from 2026-01-08 to 2026-11-09
| Company | Round | Amount | Announced | Role |
|---|---|---|---|---|
Delix Therapeutics A clinical-stage neuroscience company pioneering the discovery and development of neuroplastogens | Series C Verified against 4 of 28 sources | $100M | 2026-11-09 | [ LEAD ] |
Link Cell Therapies An oncology cell therapy company utilizing its proprietary logic-gating technology to develop next-generation CAR-T therapeutics for solid tumors and hematologic malignancies | Series A Verified against 4 of 6 sources | $30M | 2026-09-28 | [ LEAD ] |
EpiBiologics They develop bispecific antibodies designed to selectively degrade disease-causing extracellular proteins. | Series B Verified against 1 source[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $107M | 2026-01-08 | [ LEAD ] |